Adenocarcinoma
Drug research and approvals for adenocarcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 2,163 studies of adenocarcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 73 drug trials for it since 2013, FDA has 17 approved and 19 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 2,163
- Trials authorized in Canada: 73
- FDA orphan approvals: 17
- EU medicines: 4
Recruiting Now
Newest start dates first, of 2,163 recruiting on ClinicalTrials.gov ↗- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced…NCT07619521 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jun 1, 2027
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard…NCT07551596 · Phase 2 · National Cancer Institute (NCI) · starts May 25, 2027
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell…NCT07516366 · Phase 2 · National Cancer Institute (NCI) · starts May 17, 2027
- Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination DeficiencyNCT07565155 · Phase 2 · University of Miami · starts Jan 1, 2027
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic…NCT07645651 · Phase 1 · University of Washington · starts Dec 1, 2026
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate…NCT07466498 · Phase 2 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · Phase 1 · University of Pennsylvania · starts Dec 1, 2026
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803…NCT07574541 · Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityNCT06406465 · Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
Trials Authorized in Canada
The 10 newest of 73; search them all in Canada trials| Sep 3, 2026 | A phase 3, randomized, open-label study of zoldonrasib (rmc-9805) plus daraxonrasib (rmc-6236) versus gemcitabine and nab-paclitaxel as first-line treatment in…DARAXONRASIB (RMC-6236) / ZOLDONRASIB (RMC-9805) | Revolution Medicines | Pending |
| Aug 19, 2026 | A phase Ib, multicenter, randomized study evaluating the safety and activity of gdc-7035 with anti-cancer therapies as first-line treatment in patients with…GDC-7035 (RO7782493) / PANITUMUMAB / OXALIPLATIN / IRINOTECAN / GEMCITABINE /… | Roche | Pending |
| Jul 20, 2026 | A phase 2, open-label study of vs-7375, an oral kras g12d (on/off) inhibitor, as monotherapy and with cetuximab, in patients with metastatic kras g12d-mutated…VS-7375 (GFH375) / ERBITUX (CETUXIMAB) / VECTIBIX (PANITUMUMAB) | VERASTEM ONCOLOGY | Ongoing |
| Jun 5, 2026 | A phase 3, randomized, double-blind, placebo-controlled study of investigator choice of chemotherapy (modified folfirinox or gemcitabine plus nabpaclitaxel)…ZOLDONRASIB (RMC-9805) / OXALIPLATIN / 5-FLUOROURACIL / FOLINIC ACID /… | Revolution Medicines | Pending |
| May 22, 2026 | A multicenter, first-in-human, dose escalation and optimization phase I/iia study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040 | TUBULIS GMBH | Pending |
| May 19, 2026 | Restage (repurposing statins to improve outcomes in gastroesophageal cancer) trial: a phase II randomized open-label trial of perioperative simvastatin plus…SIMVASTATIN | RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE | Pending |
| May 12, 2026 | A randomized, double-blind, phase 3 study of chemotherapy with or without incb161734 in previously untreated, kras g12d–mutated metastatic pancreatic ductal…INCB161734 / NAB-PACLITAXEL / GEMCITABINE / 5-FLUOROURACIL / IRINOTECAN /… | Incyte Corporation | Ongoing |
| May 6, 2026 | Phase 2/3 open label randomized study of telisotuzumab adizutecan in combination with folfox compared to standard of care in subjects with first- line…ABBV-400 (TELISOTUZUMAB ADIZUTECAN) / FLUOROURACIL / FOLINIC ACID / OXALIPLATIN… | AbbVie | Pending |
| Apr 29, 2026 | Rasolute 303: a phase 3 global, multicenter, open-label, randomized, 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nabpaclitaxel…DARAXONRASIB (RMC-6236) / GEMCITABINE / NAB-PACLITAXEL | Revolution Medicines | Ongoing |
| Mar 12, 2026 | A phase 2/3 interventional study of pf-08634404 in combination with chemotherapy in treatment-naive participants with locally advanced or metastatic gastric,…PF-08634404 / FLUOROURACIL / CALCIUM FOLINATE / OXALIPLATIN / CAPECITABINE /… | Pfizer | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 36| Aug 26, 2026 | Rasonquetreatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not… | Revolution Medicines, Inc. | Approved |
| Dec 4, 2024 | Bizengritreatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with… | Partner Therapeutics, Inc. | Approved |
| Feb 13, 2024 | Onivydein combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Nov 16, 2023 | Keytrudain combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced… | MSD International Business GmbH | Approved |
| Nov 15, 2023 | Augtyrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) | Bristol Myers Squibb Company | Approved |
| May 5, 2021 | Keytrudain combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with… | MSD International Business GmbH | Approved |
| Jan 15, 2021 | Enhertutreatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who… | Daiichi Sankyo, Inc. | Approved |
| Dec 27, 2019 | LynparzaLynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic… | AstraZeneca Pharmaceuticals LP | Approved |
| Feb 22, 2019 | LONSURFLONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously… | Taiho Oncology, Inc. | Approved |
| Sep 22, 2017 | KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction… | MSD International Business GmbH | Approved |
| Oct 22, 2015 | irinotecan liposome injectionFor use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Nov 5, 2014 | CYRAMZATreatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after… | Eli Lilly and Company | Approved |
| Apr 21, 2014 | CYRAMZACYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction… | Eli Lilly and Company | Approved |
| Sep 6, 2013 | AbraxaneTreatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. | Abraxis BioScience, LLC | Approved |
| Apr 29, 2011 | FusilevFor use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer | Acrotech Biopharma LLC | Approved |
Medicines Authorised in the EU
Newest first| Nov 10, 2017 | Tookadpadeliporfin | STEBA Biotech S.A | EMA ↗ |
| Oct 14, 2016 | Onivyde pegylated liposomal (previously Onivyde)irinotecan hydrochloride trihydrate · orphan | Les Laboratoires Servier | EMA ↗ |
| Dec 19, 2014 | Cyramzaramucirumab | Eli Lilly Nederland B.V. | EMA ↗ |
| Nov 21, 2014 | Vargatefnintedanib | Boehringer Ingelheim International GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA